Mucocutaneous manifestations of COVID-19-associated mucormycosis: A retrospective cross-sectional study

Simple item page
dc.contributor.authorSachan, Sonalen_US
dc.contributor.authorSuvirya, Swastikaen_US
dc.contributor.authorYadav, Krishnaen_US
dc.contributor.authorGupta, Prashanten_US
dc.contributor.authorSaraswat, Abiren_US
dc.contributor.authorVerma, Parulen_US
dc.contributor.authorChandra, Ushaen_US
dc.contributor.authorSingh, Balendra Pratapen_US
dc.contributor.authorChaudhary, Shyam Chanden_US
dc.contributor.authorDwivedi, Durgesh Kumaren_US
dc.contributor.authorGarg, Ravindra Kumaren_US
dc.contributor.authorSinghai, Atinen_US
dc.contributor.authorMalhotra, Kiran Preeten_US
dc.contributor.authorParihar, Aniten_US
dc.contributor.authorKumar, Saurabhen_US
dc.date.accessioned2023-08-10T07:30:55Z
dc.date.available2023-08-10T07:30:55Z
dc.date.issued2023-08
dc.description.abstractBackground: Cutaneous mucormycosis has shown a significant upsurge during the COVID-19 pandemic. Due to the rapid progression and high mortality of cutaneous mucormycosis in this context, it is important to identify it early. However, very few studies report detailed clinical descriptions of cutaneous mucormycosis in COVID-19 patients. Objectives: To describe mucocutaneous lesions of COVID-19-associated mucormycosis based on clinical morphology and attempt to correlate them with radiological changes. Methods: A retrospective cross-sectional study was conducted at a tertiary care centre from 1st April to 31st July 2021. Eligibility criteria included hospitalised adult patients of COVID-19-associated mucormycosis with mucocutaneous lesions. Results: All subjects were recently recovering COVID-19 patients diagnosed with cutaneous mucormycosis. One of fifty-three (2%) patients had primary cutaneous mucormycosis, and all of the rest had secondary cutaneous mucormycosis. Secondary cutaneous mucormycosis lesions presented as cutaneous-abscess in 25/52 (48%), nodulo-pustular lesions in 1/52 (2%), necrotic eschar in 1/52 (2%) and ulcero-necrotic in 1/52 (2%). Mucosal lesions were of three broad sub-types: ulcero-necrotic in 1/52 (2%), pustular in 2/52 (4%) and plaques in 1/52 (2%). Twenty out of fifty-two patients (38%) presented with simultaneous mucosal and cutaneous lesions belonging to the above categories. Magnetic resonance imaging of the face showed variable features of cutaneous and subcutaneous tissue involvement, viz. peripherally enhancing collection in the abscess group, “dot in circle sign” and heterogeneous contrast enhancement in the nodulo-pustular group; and fat stranding with infiltration of subcutaneous tissue in cases with necrotic eschar and ulcero-necrotic lesions. Limitations: The morphological variety of cutaneous mucormycosis patients in a single-centre study like ours might not be very precise. Thus, there is a need to conduct multi-centric prospective studies with larger sample sizes in the future to substantiate our morphological and radiological findings. Conclusions: COVID-19-associated mucormycosis patients in our study presented with a few specific types of mucocutaneous manifestations, with distinct magnetic resonance imaging findings. If corroborated by larger studies, these observations would be helpful in the early diagnosis of this serious illness.en_US
dc.identifier.affiliationsDepartment of Dermatology, Venereology and Leprosy, Hind Institute of Medical Sciences, Barabankien_US
dc.identifier.affiliationsDepartments of Dermatology, Venereology and Leprosyen_US
dc.identifier.affiliationsRadiodiagnosisen_US
dc.identifier.affiliationsMicrobiology, King George’s Medical Universityen_US
dc.identifier.affiliationsDepartment of Dermatology, Indushree Skin Clinic, Lucknowen_US
dc.identifier.affiliationsDepartment of Dermatology, Venereology and Leprosy, Lala Lajpat Rai Memorial Medical College, Meeruten_US
dc.identifier.affiliationsDepartments of Prosthodonticsen_US
dc.identifier.affiliationsMedicineen_US
dc.identifier.affiliationsNeurologyen_US
dc.identifier.affiliationsPathology, King George’s Medical Universityen_US
dc.identifier.affiliationsDepartment of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationSachan, Sonalen_US
dc.identifier.citationSuvirya, Swastikaen_US
dc.identifier.citationYadav, Krishnaen_US
dc.identifier.citationGupta, Prashanten_US
dc.identifier.citationSaraswat, Abiren_US
dc.identifier.citationVerma, Parulen_US
dc.identifier.citationChandra, Ushaen_US
dc.identifier.citationSingh, Balendra Pratapen_US
dc.identifier.citationChaudhary, Shyam Chanden_US
dc.identifier.citationDwivedi, Durgesh Kumaren_US
dc.identifier.citationGarg, Ravindra Kumaren_US
dc.identifier.citationSinghai, Atinen_US
dc.identifier.citationMalhotra, Kiran Preeten_US
dc.identifier.citationParihar, Aniten_US
dc.identifier.citationKumar, Saurabh. Mucocutaneous manifestations of COVID-19-associated mucormycosis: A retrospective cross-sectional study. Indian Journal of Dermatology, Venereology and Leprology. 2023 Aug; 89(4): 510-523en_US
dc.identifier.issn0973-3922
dc.identifier.issn0378-6323
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223152
dc.languageenen_US
dc.publisherScientific Scholaren_US
dc.relation.issuenumber4en_US
dc.relation.volume89en_US
dc.source.urihttps://doi.org/10.25259/IJDVL_277_2022en_US
dc.subjectCOVID-19-associated mucormycosisen_US
dc.subjectcutaneous mucormycosisen_US
dc.titleMucocutaneous manifestations of COVID-19-associated mucormycosis: A retrospective cross-sectional studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJDVL2023v89n4p510.pdf
Size:
10.05 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology